Nestle Sells Peanut-Allergy Treatment Business to Stallergenes Greer

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 97%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

By Adria Calatayud Nestle said it has sold its Palforzia peanut-allergy treatment business to biopharmaceutical company Stallergenes Greer. The Swiss...

Nestle said it has sold its Palforzia peanut-allergy treatment business to biopharmaceutical company Stallergenes Greer.

The Swiss consumer-goods company said Monday that it will receive milestone payments and royalties from Stallergenes Greer. The deal was closed upon signing, Nestle said. The sale allows Nestle's health-science operations to focus on its core strengths and key growth drivers, the unit's Chief Executive Greg Behar said.

Nestle last year said that it would conduct a strategic review of Palforzia after a slower-than-expected adoption by patients and healthcare professionals.

 

コメントありがとうございます。コメントは審査後に公開されます。
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 3. in JP

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Nestle divests peanut allergy business Palforzia By ReutersNestle divests peanut allergy business Palforzia
ソース: Investingcom - 🏆 450. / 53 続きを読む »

Nestle divests peanut allergy business PalforziaNestle has divested its peanut allergy treatment business Palforzia, the Swiss food company said on Monday, following its strategic review of the division.
ソース: Reuters - 🏆 2. / 97 続きを読む »